esg206
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2022 (NCT05263739)
Timeline
No events for the selected filters.
Indications
Mechanism of action
- DNA topoisomerase IINHIBITOR
TOP1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06853444 | Phase 1/Phase 2 (Phase 2) | Mar 25, 2025 | Shandong University |
| NCT05822843 | Phase 1 | Aug 2, 2023 | — |
| NCT05263739 | Phase 1 | Sep 30, 2022 | — |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shandong University | Academic/Hospital | 1 | 0 | 1 | 2025 |
1 organizations
Page 1 / 1